CBD) was approved by the FDA in 2018 for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, and other companies (Tilray, MMJ Phytotech, Insys) have clinical trials underway in seizure disorders as well. CBD Hemp Cultivation (Neivert) According to the National Confere

ll as detailed discussions of 21 public and private operators that currently have exposure to the category, including Outperform rated Canopy Growth, Tilray and Turning Point Brands, which have all announced plans to enter the U.S. CBD market. The Science of CBD (Nadeau) Cannabis’s therapeutic potential

Important Disclosures Relating to Cowen Research Cowen and Company, LLC and or its affiliates make a market in the stock of GW Pharmaceuticals Plc, Tilray, Turning Point Brands and Canopy Growth Corporation securities. Cowen and Company, LLC served as the placement agent in connection with Tilray's Ser

Plc, Tilray, Turning Point Brands and Canopy Growth Corporation securities. Cowen and Company, LLC served as the placement agent in connection with Tilray's Series A preferred stock financing in February and March 2018. Cowen and Company, LLC managed or co-managed a public offering of GW Pharmaceutical